FCGR3A and cancer: A promising avenue is the use of CARs not based on a single-chain antibody variable fragment (for direct antigen recognition) but on the activating Fc-receptor CD16.11 This platform requires co-administration of monoclonal antibodies and CD16 CAR T cells for cancer recognition.